4.7 Article

Improved membrane transport of astaxanthine by liposomal encapsulation

Journal

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2010.03.004

Keywords

Cell cycle arrest; Antioxidative enzymes; Hepatoma cells; Nanoencapsulation; Blood-Brain Barrier; Radiation therapy

Funding

  1. National Science Council (Taiwan) [NSC-97-2313-B-241-002]

Ask authors/readers for more resources

Astaxanthine (3,3'-dihydroxy-beta,beta'-caroten-4,4'-dione) (AST), a red-colored carotenoid pigment, possesses extremely powerful antioxidative activity. However, its drawbacks reside in poor solubility in aqueous system, resulting in extremely low bioavailability. To ameliorate such defects, we prepared AST encapsulated within liposomes (AST-L) and tested with Hep3B and HepG2 cell lines. AST-L had size 251 +/- 23 nm with AST content 89.0 +/- 8.6 mg/g. AST-L apparently showed improved stability and transportability. The overall transport time was 7.55 h and 6.00 h for free AST and AST-L, respectively. AST-L more effectively activated antioxidant enzymes like superoxide dismutase, catalase and glutathione S-transferase than free AST. Hep3B consumed AST more rapidly than HepG2 cell lines. Moreover, AST-L when combined with gamma radiation (10 Gy) therapy potentially triggered subG(1) arrest in Hep3B and HepG2 cell lines in a dose-responsive manner (p < 0.05). To conclude, the poor bioavailability of AST can be improved by liposomal encapsulation, which can be a good adjuvant remedy in gamma radiotherapy. (C) 2010 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available